- Home
- BCDA vs PRPH Comparison
BCDA vs PRPH Comparison
Compare BCDA & PRPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- PRPH
- Stock Information
- Founded
- BCDA N/A
- PRPH 1989
- Country
- BCDA United States
- PRPH United States
- Employees
- BCDA N/A
- PRPH N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- PRPH Biotechnology: Pharmaceutical Preparations
- Sector
- BCDA Health Care
- PRPH Health Care
- Exchange
- BCDA Nasdaq
- PRPH Nasdaq
- Market Cap
- BCDA 9.4M
- PRPH 10.7M
- IPO Year
- BCDA N/A
- PRPH 1997
- Fundamental
- Price
- BCDA $2.66
- PRPH $0.31
- Analyst Decision
- BCDA Strong Buy
- PRPH
- Analyst Count
- BCDA 1
- PRPH 0
- Target Price
- BCDA $25.00
- PRPH N/A
- AVG Volume (30 Days)
- BCDA 41.8K
- PRPH 7.2M
- Earning Date
- BCDA 05-13-2025
- PRPH 05-08-2025
- Dividend Yield
- BCDA N/A
- PRPH N/A
- EPS Growth
- BCDA N/A
- PRPH N/A
- EPS
- BCDA N/A
- PRPH N/A
- Revenue
- BCDA $71,000.00
- PRPH $12,753,000.00
- Revenue This Year
- BCDA N/A
- PRPH $36.93
- Revenue Next Year
- BCDA N/A
- PRPH $132.05
- P/E Ratio
- BCDA N/A
- PRPH N/A
- Revenue Growth
- BCDA N/A
- PRPH N/A
- 52 Week Low
- BCDA $1.63
- PRPH $0.22
- 52 Week High
- BCDA $6.45
- PRPH $7.48
- Technical
- Relative Strength Index (RSI)
- BCDA 57.48
- PRPH 36.66
- Support Level
- BCDA $2.47
- PRPH $0.31
- Resistance Level
- BCDA $2.69
- PRPH $0.46
- Average True Range (ATR)
- BCDA 0.17
- PRPH 0.05
- MACD
- BCDA 0.01
- PRPH -0.01
- Stochastic Oscillator
- BCDA 66.67
- PRPH 0.00
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About PRPH ProPhase Labs Inc. (DE)
ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.